April 3, 2023 07:22 AM EDTUpdated 12:03 PM
People

Vedere Bio II, gene ther­a­py biotech born out of No­var­tis buy­out, clos­es down

Amber Tong

When No­var­tis swooped in to buy Vedere Bio and its pre­clin­i­cal gene ther­a­py for $150 mil­lion up­front in 2020, Vedere CEO Cyrus Moza­yeni …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

A look at biotech's year of the megaround

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

A service from the Financial Times